查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012374

晶片器官市場：2026-2032年全球市場預測（按材料、產品、技術、器官類型、應用和最終用戶分類）

Organs-on-chips Market by Material, Product, Technology, Organ Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，「晶片器官」市值將達到 2.1296 億美元，到 2026 年將成長到 2.7879 億美元，到 2032 年將達到 17.6249 億美元，年複合成長率為 35.24%。

主要市場統計數據
基準年 2025 2.1296億美元
預計年份：2026年 2.7879億美元
預測年份 2032 1,762,490,000 美元
複合年成長率 (%) 35.24%

簡要概述晶片類器官的發展歷程、相關人員的優先事項以及將微生理系統整合到轉化流程中的策略需求。

晶片類器官技術已從最初的學術研究發展成為一項核心技術，能夠更真實地在體外重現人類生理功能。本文將這項技術置於研究機構和產業領導者的策略議程。早期研究著重於驗證可行性，而如今的研究重點已轉向可重複性、與標準化實驗流程的整合以及與下游發現和轉化流程的兼容性。因此，開發人員和採用者現在不僅從生物學保真度的角度評估平台，還會從材料、可製造性和資料互通性等方面進行考慮。

快速的技術成熟、模組化整合以及終端用戶期望的變化正在重塑晶片器官創新的部署路徑和商業策略。

晶片器官（OCC）領域正經歷著一場變革性的轉型，其特點是技術日趨成熟、工作流程整合以及資助者和監管機構期望的轉變，所有這些都在重塑其應用路徑。新的製造方法和材料科學的創新縮小了原型產品與量產設備之間的差距。如今，玻璃、PDMS 和熱塑性塑膠之間的選擇體現了生物相容性、光學透明度和生產可擴展性之間的權衡。因此，各機構正在修訂其平台藍圖，優先考慮與自動化處理和成像系統的兼容性。

評估 2025 年推出的新關稅政策對供應鏈、採購決策以及研發計畫的累積營運和策略影響。

2025年關稅上調的實施迫使產業相關人員重新評估其供應鏈策略、採購時機以及零件和成品系統的地域採購決策，這些影響累積整個價值鏈。許多設備製造商依賴精密玻璃、PDMS和熱塑性塑膠等聚合物基板、微加工模具以及外包測量模組等專用組件。當關稅影響原料和子組件的進口時，製造商將面臨更高的接收成本，進而影響定價、供應商選擇和庫存管理決策。因此，各團隊正在採取對沖策略，例如多通路採購、增加本地庫存，以及在某些情況下，將部分組裝業務轉移到更靠近關鍵客戶所在地的地方。

詳細的細分分析揭示了材料、產品、技術、最終用戶、應用和器官特定選擇如何影響部署、檢驗和商業策略。

細分市場的特定趨勢影響開發者和買家對平台的優先排序，而了解這些細微差別對於有效的產品組合管理至關重要。材料選擇，例如玻璃、PDMS 和熱塑性塑膠，不僅影響裝置性能，還影響其在高內涵成像中的光學適用性以及規模化生產的可行性。玻璃具有優異的光學性能和耐化學性，但會增加製造複雜性。 PDMS 在快速原型製作和透氣滲透性方面仍然具有吸引力，而熱塑性塑膠則具有工業化生產的優勢，如果產量足以支撐模具投資，則可以降低單位成本。

區域間在製造能力、法規環境和研究生態系統的差異如何影響全球商業化和供應鏈策略？

區域趨勢對供應鏈韌性、監管方式和夥伴關係策略有著根本性的影響，因此，了解地域差異對於部署和商業化規劃至關重要。在美洲，成熟的製藥和生物技術中心強勁的需求推動了產品的早期商業性化應用，而對本地組裝和與契約製造合作的投資則有助於降低跨境關稅和運輸中斷帶來的風險。該地區的學術研究中心和Start-Ups持續為創新管道做出貢獻，而圍繞生命科學投資的區域政策舉措正在促進轉化合作，將醫療設備開發商與臨床和臨床前試驗基地聯繫起來。

耗材、設備和軟體的垂直整合推動了競爭與合作的動態，以及檢驗的工作流程和可製造材料的策略價值。

隨著各公司不斷提升其在設備工程、生物製劑整合和軟體分析方面的能力，晶片器官領域的競爭格局正在改變。策略差異化越來越依賴協調整個生態系統的能力，而非單一技術的優勢。無論是主要企業還是創新型Start-Ups，都在致力於垂直整合的解決方案，將高品質的耗材（例如微孔盤和試劑）與強大的儀器和以數據為中心的軟體相結合，從而降低終端用戶的技術准入門檻，並創造永續的商機。

為高階主管提供切實可行的策略和營運步驟，以加速採用、降低驗證風險，並建構強大且擴充性的「晶片器官」經營模式。

產業領導企業應採取一系列切實可行的措施，在技術能力與商業性和營運韌性之間取得平衡，從而在控制實施風險的同時加速技術應用。首先，在研發週期的早期階段評估玻璃、PDMS 和熱塑性材料等選項，並優先制定兼顧生物性能和可製造性的材料策略，以減少後期研發過程中可能出現的意外問題和檢驗負擔。其次，設計產品藍圖，將微孔盤和試劑等耗材與儀器和軟體整合，從而創建無縫的工作流程。耗材和儀器的捆綁銷售可以最佳化生命週期成本並加強客戶關係。

結合相關人員訪談、技術評估和區域供應鏈分析的嚴謹混合方法研究途徑，有助於制定可行的部署方案和夥伴關係決策。

本研究採用混合方法，結合定性產業訪談、技術文獻綜述以及設備架構和供應鏈路徑的比較分析，以確保對科學、商業性和營運因素的平衡理解。透過與學術機構、生物技術公司、受託研究機構和製藥公司等相關人員的結構化訪談，收集了關鍵見解，觀點涵蓋了檢驗標準、採購慣例以及與現有研發工作流程整合所面臨的挑戰。

深入分析技術嚴謹性、材料策略和供應鏈韌性如何決定器官晶片在研究和工業領域的應用速度和範圍。

總之，當開發者和買家就可重複性、材料策略和整合能力達成一致時，晶片器官正從一個實驗平台演變為一種實用工具，對藥物發現、毒性評估和個人化醫療產生重大影響。材料選擇、裝置架構以及耗材生態系統之間的相互作用不僅影響實驗結果，也影響著面向不同終端用戶規模化生產和商業化解決方案的可行性。在研發早期階段解決供應鏈韌性和監管合合格，可以降低下游風險，並使合約研究組織 (CRO) 和製藥合作夥伴能夠更可靠地採用該技術。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：晶片器官市場：依材料分類

  • 玻璃
  • PDMS
  • 熱塑性樹脂

第9章 晶片器官市場：依產品分類

  • 消耗品
    • 微孔盤
    • 試劑
  • 裝置
  • 軟體

第10章 晶片器官市場：依技術分類

  • 微流體晶片
    • 多層晶片
    • 單層晶片
  • 多重器官晶片
  • 單一器官晶片

第11章 晶片器官市場（依器官分類）

  • 腸子
  • 心
  • 腎
  • 肝
    • 基於肝細胞的
    • 球狀貝斯
  • 肺

第12章 晶片器官市場：依應用領域分類

  • 疾病模型
  • 藥物發現
    • 高通量篩檢
    • 先導藥物最適化
  • 個人化醫療
  • 毒性測試

第13章 晶片器官市場：依最終用戶分類

  • 學術機構
  • 生技公司
  • 合約研究機構
  • 製藥公司
    • 全球製藥公司
    • 專業製藥公司

第14章 晶片器官市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 晶片器官市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 晶片器官市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國晶片器官市場

第18章：中國器官晶片市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AIM Biotech Pte. Ltd.
  • Altis Biosystems
  • AlveoliX AG
  • Bi/ond BV
  • BiomimX Srl
  • Cherry Biotech
  • CN Bio Innovations Ltd.
  • Dynamic42 GmbH
  • Elvesys Group
  • Emulate Inc.
  • Hesperos Inc.
  • InSphero AG
  • Kirkstall Ltd.
  • Lena Biosciences Inc.
  • MEPSGEN Co., Ltd.
  • MIMETAS BV
  • NETRI SAS
  • Nortis Inc.
  • Obatala Sciences
  • React4life
  • SynVivo Inc.
  • The Charles Stark Draper Laboratory Inc.
  • TissUse GmbH
Product Code: MRR-431C35F6C22A

The Organs-on-chips Market was valued at USD 212.96 million in 2025 and is projected to grow to USD 278.79 million in 2026, with a CAGR of 35.24%, reaching USD 1,762.49 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 212.96 million
Estimated Year [2026] USD 278.79 million
Forecast Year [2032] USD 1,762.49 million
CAGR (%) 35.24%

A concise overview of organs-on-chips evolution, stakeholder priorities, and the strategic imperative for integrating microphysiological systems into translational pipelines

The organs-on-chips field has matured from academic curiosity to a pivotal technology enabling closer replication of human physiology outside the body, and this introduction situates the technology within the strategic agendas of research institutions and industry leaders. Early work focused on demonstrating feasibility; today emphasis has shifted toward reproducibility, integration with standardized laboratory workflows, and compatibility with downstream discovery and translational pipelines. As a result, developers and adopters increasingly evaluate platforms not only for biological fidelity but also for materials, manufacturability, and data interoperability.

Across laboratories and commercial teams, material choices such as Glass, PDMS, and Thermoplastics drive device performance, manufacturability, and regulatory acceptability, shaping design decisions from prototyping through scaled production. Concurrently, the product landscape spans Consumables, Instruments, and Software; consumables encompass essential items including Microplates and Reagents that determine day-to-day experiment throughput and cost structure. Technology modalities vary from Microfluidic Chips, which include both Multi Layer Chips and Single Layer Chips, to Multi Organ Chips and Single Organ Chips, enabling applications that range from focused organ studies to interconnected system-level investigations.

End users span Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, the latter of which includes both Global Pharma and Specialty Pharma entities with differing risk tolerances and adoption timelines. Common applications include Disease Modeling, Drug Discovery with High Throughput Screening and Lead Optimization activities, Personalized Medicine, and Toxicity Testing. Organ types addressed in current development efforts include Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based strategies, and Lung, each presenting distinct biological, analytical, and regulatory challenges. This introduction frames the remainder of the executive summary by highlighting the converging priorities of biological relevance, industrial scalability, and integration into established R&D workflows.

How rapid technological maturation, modular integration, and changing end-user expectations are reshaping adoption pathways and commercial strategies in organ-on-chip innovation

The organs-on-chips landscape is undergoing transformative shifts characterized by technological maturation, consolidation of workflows, and evolving expectations from funders and regulators, and these changes are reshaping adoption pathways. New fabrication approaches and materials science innovations have reduced the gap between prototyping and manufacturable devices; the choice between Glass, PDMS, and Thermoplastics now reflects a deliberate trade-off among biological compatibility, optical clarity, and production scalability. As a result, organizations are re-evaluating platform roadmaps to prioritize compatibility with automated handling and imaging systems.

In product strategy, the industry is moving beyond siloed instruments toward integrated solutions that pair consumables such as Microplates and Reagents with interoperable Instruments and Software, enabling end users to deploy workflows with less in-house engineering overhead. The microfluidic technology base itself is diversifying; Multi Layer Chips and Single Layer Chips offer different fluidic control and fabrication cost profiles, while Multi Organ Chips create opportunities for system-level pharmacology and single organ chips retain roles in focused mechanistic studies. This technological diversification is accompanied by deeper engagement from Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, the latter with distinct priorities between Global Pharma and Specialty Pharma players.

Applications are broadening in parallel: Disease Modeling and Toxicity Testing remain core, while Drug Discovery workflows increasingly incorporate High Throughput Screening and Lead Optimization stages tailored to organ-specific readouts. Personalized Medicine initiatives are leveraging patient-derived cells in organ-specific contexts like Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based liver systems, and Lung, driving renewed attention to donor variability, cell sourcing, and standardized protocols. These shifts collectively emphasize interoperability, standardization, and data robustness as the criteria that will separate widely adopted platforms from niche academic prototypes.

An assessment of the cumulative operational and strategic effects of newly implemented tariff policies on supply chains, sourcing decisions, and R&D timelines in 2025

The introduction of elevated tariff measures in 2025 has compelled industry participants to reassess supply chain strategies, procurement timing, and geographic sourcing decisions for components and finished systems, and these effects are cumulative across the value chain. Many device makers rely on specialized components, including precision glass, polymer substrates such as PDMS and thermoplastic resins, microfabrication tooling, and outsourced instrumentation modules. When tariffs affect imports of raw materials or subassemblies, manufacturers confront higher landed costs that influence decisions about pricing, vendor selection, and inventory management. Consequently, teams are deploying hedging strategies, including multi-sourcing, increased local stocking, and in some cases, partial relocation of assembly activities closer to key customer bases.

For consumables-Microplates and Reagents in particular-the tariff environment has amplified incentives to localize reagent production or to qualify multiple suppliers across jurisdictions to avoid single points of failure. Software and digital deliverables are less directly impacted by tariffs but encounter knock-on effects through delays in hardware shipments and integration testing, which in turn affect project timelines for instrument-based deployments. In addition, Contract Research Organizations and biotechnology firms that depend on imported instrumentation have had to revisit project budgets and timelines to incorporate procurement lead times, customs clearance variability, and potential retesting to ensure regulatory compliance when components are re-sourced.

These operational adjustments are also influencing strategic partnerships. Companies are increasingly open to co-manufacturing agreements, strategic sourcing alliances, and regional distribution partnerships to mitigate tariff exposure. Regulatory considerations intersect with trade policy; for example, qualification of alternative materials or substitutes may trigger additional validation requirements, particularly for liver models that depend on Hepatocyte Based or Spheroid Based systems where biological performance must be demonstrated. In sum, the cumulative impact of tariff changes has led to more resilient, albeit more complex, supply chain designs and has accelerated conversations about nearshoring, supplier diversification, and long-term contractual arrangements with manufacturers and distributors.

Detailed segmentation analysis revealing how material, product, technology, end-user, application, and organ-specific choices influence adoption, validation, and commercial strategy

Segment-specific dynamics shape how developers and purchasers prioritize platforms, and understanding these nuances is essential for effective portfolio management. Material choices among Glass, PDMS, and Thermoplastics influence not only device performance but also optical compatibility for high-content imaging and the feasibility of scaling production. Glass offers excellent optical properties and chemical resistance but can raise fabrication complexity; PDMS remains attractive for rapid prototyping and gas permeability, whereas Thermoplastics provide industrial manufacturability and lower per-unit costs when volumes justify tooling investments.

Product segmentation into Consumables, Instruments, and Software highlights differing margins, service models, and customer interactions. Consumables, which include Microplates and Reagents, generate recurring revenue and require robust supply chain continuity; Instruments demand higher upfront investment and are often paired with long-term service contracts; Software enables data standardization, analytics, and integration with laboratory information management systems, influencing stickiness and cross-sell potential. Within technology choices, Microfluidic Chips present both Multi Layer Chips and Single Layer Chips variants that trade off control complexity against ease of manufacture, while Multi Organ Chips enable emergent phenotypes relevant to systemic pharmacology and Single Organ Chips support targeted mechanistic studies.

End users exhibit distinct adoption behaviors: Academic Institutes prioritize flexibility and cost-effectiveness for hypothesis-driven research; Biotechnology Companies emphasize speed to proof-of-concept and potential for platform licensing; Contract Research Organizations focus on throughput, repeatability, and compliance; Pharmaceutical Companies, whether Global Pharma or Specialty Pharma, evaluate platforms through the lens of portfolio alignment, regulatory risk reduction, and potential to accelerate candidate selection. Applications drive technical and operational requirements: Disease Modeling and Toxicity Testing demand physiological fidelity and validated readouts, Drug Discovery workflows such as High Throughput Screening and Lead Optimization require scalability and automation, and Personalized Medicine depends on compatibility with patient-derived cells. Organ-specific considerations-Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based strategies, and Lung-further determine cell sourcing, assay development, and validation pathways. Integrating these segmentation lenses enables more precise prioritization of R&D investment and commercial go-to-market tactics.

How geographic differences in manufacturing strength, regulatory environments, and research ecosystems shape commercialization and supply chain strategies globally

Regional dynamics fundamentally influence supply chain resilience, regulatory approaches, and partnership strategies, and understanding geographic variation is critical for deployment and commercialization plans. In the Americas, strong demand from established pharmaceutical and biotechnology hubs is driving early commercial uptake, supporting investments in localized assembly and partnerships with contract manufacturers to reduce exposure to cross-border tariffs and shipping disruptions. Academic research centers and startups in the region continue to contribute to innovation pipelines, and regional policy initiatives around life sciences investment are encouraging translational collaborations that connect device developers with clinical and preclinical testing sites.

In Europe, Middle East & Africa, regulatory harmonization efforts and a robust ecosystem of contract research organizations create an environment favorable to standardized validation and collaborative development projects. European research consortia and specialty pharma players often emphasize reproducibility and compliance with stringent safety frameworks, which inform material selection and device qualification strategies. Across the Middle East and Africa, nascent adoption is driven by targeted academic-industry partnerships and investments in translational capacity-building.

Asia-Pacific presents a diverse landscape, with strong manufacturing capabilities, extensive supply chains for thermoplastic components, and significant growth in biotechnology entrepreneurship. The region's manufacturing depth supports rapid scaling of consumables and instruments, while major research universities and CROs foster use cases in Drug Discovery, Disease Modeling, and toxicity assessment. These geographic differences mean that companies must tailor commercialization and partnership models to regional strengths, balancing proximity to end users with access to specialized suppliers and regulatory pathways.

Competitive and partnership dynamics driven by vertical integration of consumables, instrumentation, and software, and the strategic value of validated workflows and manufacturable materials

Competitive dynamics in the organs-on-chips domain are evolving as companies refine capabilities across device engineering, biologics integration, and software analytics, and strategic differentiation increasingly rests on ecosystem orchestration rather than single-technology advantage. Leading firms and innovative startups alike are focusing on vertically integrated offerings that combine high-quality consumables such as Microplates and Reagents with robust Instruments and data-centric Software, which together lower the technical entry barrier for end users and create recurring revenue opportunities.

Organizations that can demonstrate validated workflows for critical applications such as Disease Modeling and Toxicity Testing, and who can align device materials with manufacturability considerations spanning Glass, PDMS, and Thermoplastics, are better positioned to secure strategic partnerships with Contract Research Organizations and pharmaceutical partners. Similarly, technology leaders who offer flexible microfluidic architectures-balancing Multi Layer Chips and Single Layer Chips capabilities along with Multi Organ and Single Organ configurations-create value by addressing both high-throughput discovery requirements and detailed mechanistic studies. Strategic moves such as licensing biological models, forming reagent supply alliances, and investing in software platforms that enable standardized data capture and analytics are shaping the competitive landscape.

Buy-side behavior also favors providers that can support varied end users, from Academic Institutes seeking cost-effective, adaptable systems to Global Pharma requiring rigorous validation and Specialty Pharma interested in niche applications. Companies that invest in regulatory expertise, scalable manufacturing, and service infrastructures to support long-term programs will likely see higher customer retention and broader adoption across application domains.

Practical strategic and operational steps for executives to accelerate adoption, reduce validation risk, and build resilient, scalable organ-on-chip business models

Industry leaders should pursue a set of pragmatic, actionable measures that align technological capability with commercial and operational resilience, and these moves will accelerate adoption while managing execution risk. First, prioritize material strategies that balance biological performance and manufacturability by qualifying Glass, PDMS, and Thermoplastic options early in development cycles to reduce late-stage surprises and validation burdens. Second, design product roadmaps that integrate Consumables like Microplates and Reagents with Instruments and Software to create seamless workflows; bundling consumables with instruments can improve lifecycle economics and strengthen customer relationships.

Third, diversify supply chains and establish regional manufacturing or assembly options to mitigate tariff-related and logistical risks, while negotiating multi-year agreements with key suppliers to secure continuity for critical consumables. Fourth, in technology development, maintain modularity that supports both Multi Layer Chips and Single Layer Chips variants and offers pathways to Multi Organ Chips integration, so customers can scale from single-organ studies to system-level investigations without wholesale platform replacement. Fifth, prioritize end-user engagement by developing tailored offerings for Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, with distinct service and validation packages for Global Pharma and Specialty Pharma customers.

Finally, invest in data standards and software platforms that enable reproducibility, cross-lab comparability, and integration with laboratory information systems to support Drug Discovery activities such as High Throughput Screening and Lead Optimization, as well as Disease Modeling and Personalized Medicine applications. Taken together, these steps will reduce adoption friction and create defensible commercial positions.

A rigorous mixed-methods research approach combining stakeholder interviews, technical assessments, and regional supply chain analysis to inform practical deployment and partnership decisions

This research employed a mixed-methods approach that combined qualitative industry interviews, technical literature review, and comparative analysis of device architectures and supply chain pathways, ensuring a balanced view of scientific, commercial, and operational factors. Primary insights were gathered through structured interviews with stakeholders spanning Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, which provided perspectives on validation criteria, procurement practices, and integration challenges with existing R&D workflows.

Technical assessment examined differences in material properties among Glass, PDMS, and Thermoplastics and evaluated how fabrication choices such as Multi Layer Chips versus Single Layer Chips influence manufacturability and functional readouts. The methodology also included laboratory workflow mapping to understand how Consumables including Microplates and Reagents interface with Instruments and Software across applications like Disease Modeling, Drug Discovery with High Throughput Screening and Lead Optimization, Personalized Medicine, and Toxicity Testing. Regional analysis considered manufacturing capabilities, regulatory frameworks, and ecosystem maturity across the Americas, Europe, Middle East & Africa, and Asia-Pacific to highlight pragmatic deployment considerations.

Where possible, findings were triangulated against publicly available technical reports, patent landscapes, and case studies of platform validation to ensure reliability. Throughout the process, emphasis was placed on identifying operational constraints and adoption barriers rather than projecting quantitative market trajectories, enabling recommendations that are directly actionable for R&D, commercial, and supply chain leaders.

Key takeaways on how technical rigor, materials strategy, and supply chain resilience determine the pace and breadth of organs-on-chips adoption in research and industry

In conclusion, organs-on-chips are transitioning from experimental platforms to practical tools that can materially influence drug discovery, toxicity assessment, and personalized medicine pathways, provided developers and buyers align on reproducibility, materials strategy, and integration capabilities. The interplay between material selection, device architecture, and consumable ecosystems shapes not only experimental outcomes but also the feasibility of scaling and commercializing solutions across diverse end users. Addressing supply chain resilience and regulatory qualification early in development reduces downstream risk and enables more reliable adoption by Contract Research Organizations and pharmaceutical partners.

Looking forward, companies that deliver validated, interoperable solutions and invest in software and data standardization will capture opportunities across Disease Modeling, High Throughput Screening and Lead Optimization activities, and organ-specific use cases in Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based systems, and Lung. By integrating technical rigor with pragmatic commercialization and sourcing strategies, stakeholders can accelerate impact while managing operational complexity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Organs-on-chips Market, by Material

  • 8.1. Glass
  • 8.2. PDMS
  • 8.3. Thermoplastics

9. Organs-on-chips Market, by Product

  • 9.1. Consumables
    • 9.1.1. Microplates
    • 9.1.2. Reagents
  • 9.2. Instruments
  • 9.3. Software

10. Organs-on-chips Market, by Technology

  • 10.1. Microfluidic Chips
    • 10.1.1. Multi Layer Chips
    • 10.1.2. Single Layer Chips
  • 10.2. Multi Organ Chips
  • 10.3. Single Organ Chips

11. Organs-on-chips Market, by Organ Type

  • 11.1. Gut
  • 11.2. Heart
  • 11.3. Kidney
  • 11.4. Liver
    • 11.4.1. Hepatocyte Based
    • 11.4.2. Spheroid Based
  • 11.5. Lung

12. Organs-on-chips Market, by Application

  • 12.1. Disease Modeling
  • 12.2. Drug Discovery
    • 12.2.1. High Throughput Screening
    • 12.2.2. Lead Optimization
  • 12.3. Personalized Medicine
  • 12.4. Toxicity Testing

13. Organs-on-chips Market, by End User

  • 13.1. Academic Institutes
  • 13.2. Biotechnology Companies
  • 13.3. Contract Research Organizations
  • 13.4. Pharmaceutical Companies
    • 13.4.1. Global Pharma
    • 13.4.2. Specialty Pharma

14. Organs-on-chips Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Organs-on-chips Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Organs-on-chips Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Organs-on-chips Market

18. China Organs-on-chips Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AIM Biotech Pte. Ltd.
  • 19.6. Altis Biosystems
  • 19.7. AlveoliX AG
  • 19.8. Bi/ond B.V.
  • 19.9. BiomimX S.r.l.
  • 19.10. Cherry Biotech
  • 19.11. CN Bio Innovations Ltd.
  • 19.12. Dynamic42 GmbH
  • 19.13. Elvesys Group
  • 19.14. Emulate Inc.
  • 19.15. Hesperos Inc.
  • 19.16. InSphero AG
  • 19.17. Kirkstall Ltd.
  • 19.18. Lena Biosciences Inc.
  • 19.19. MEPSGEN Co., Ltd.
  • 19.20. MIMETAS B.V.
  • 19.21. NETRI SAS
  • 19.22. Nortis Inc.
  • 19.23. Obatala Sciences
  • 19.24. React4life
  • 19.25. SynVivo Inc.
  • 19.26. The Charles Stark Draper Laboratory Inc.
  • 19.27. TissUse GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORGANS-ON-CHIPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORGANS-ON-CHIPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ORGANS-ON-CHIPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GCC ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. G7 ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. NATO ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. NATO ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA ORGANS-ON-CHIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)